Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Back to The Tape

Seeking Alpha

05 Aug 2026, 17:50 UTC · 1h ago

Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

ShareX LinkedIn

Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement

What the story claims

4 claims · each scored for market impact

What matters in this story

1
Stoke Therapeutics expects to submit a rolling NDA for zorevunersen in Q1 2027. — NDA submission is a critical regulatory milestone that moves a lead drug candidate toward commercialization.
+0.60
2
Phase 3 EMPEROR data for zorevunersen is expected in Q3 2027. — Phase 3 results are the primary binary catalyst for biotech valuations and determine the likelihood of approval.
+0.50
3
STK-002 is currently advancing through the phase 1 OSPREY study for autosomal dominant optic atrophy. — Early-stage pipeline expansion validates the underlying technology platform and reduces single-asset risk.
+0.30
4
An FDA meeting regarding zorevunersen is anticipated in the second half of 2026. — FDA meetings provide guidance on study design and requirements, though they are less impactful than data readouts.

6 related stories

GlobeNewsWire
8h ago
CAPR Legal News: Capricor Therapeutics Hit with Securities Fraud Class Action over Alleged Misrepresentations about its Clinical Data – Contact BFA Law
- biotech
- clinical trials
- fda
Read

Stoke: 'Buy' On Zorevuner… — SDTK +1.00 | NewsImpactScreener

Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement

What matters in this story

CAPR Legal News: Capricor Therapeutics Hit with Securities Fraud Class Action over Alleged Misrepresentations about its Clinical Data – Contact BFA Law

Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement

What matters in this story

CAPR Legal News: Capricor Therapeutics Hit with Securities Fraud Class Action over Alleged Misrepresentations about its Clinical Data – Contact BFA Law

How each ticker is affected

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

ROSEN, LEADING INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPR

Sagimet: A Look Ahead To Earnings And A Catalyst-Heavy H2 2026

Niagen Bioscience, Inc. (NAGE) Q2 2026 Earnings Call Transcript

Waters Q2 Earnings Beat Estimates, 2026 Revenue Growth View Raised

Here is Why Growth Investors Should Buy Harmony Biosciences (HRMY) Now

Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement

What matters in this story

Next reads from the same story arc

CAPR Legal News: Capricor Therapeutics Hit with Securities Fraud Class Action over Alleged Misrepresentations about its Clinical Data – Contact BFA Law

Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement

What matters in this story

Next reads from the same story arc

CAPR Legal News: Capricor Therapeutics Hit with Securities Fraud Class Action over Alleged Misrepresentations about its Clinical Data – Contact BFA Law

How each ticker is affected

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

ROSEN, LEADING INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPR

Sagimet: A Look Ahead To Earnings And A Catalyst-Heavy H2 2026

Niagen Bioscience, Inc. (NAGE) Q2 2026 Earnings Call Transcript

Waters Q2 Earnings Beat Estimates, 2026 Revenue Growth View Raised

Here is Why Growth Investors Should Buy Harmony Biosciences (HRMY) Now